NASDAQ:KYMR

Kymera Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy KYMR

*Your capital is at risk

$73.21

+1.92 (+2.69%)

At Close: Jun 03, 2026

Kymera Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -86.15. In total, the insiders bought 532.28K and sold 268.57K KYMR shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-86.15
● Buy	532.28K shares
● Sell	268.57K shares
49% Buy Activity Moderate Positive Correlation
Buy Signal Low Confidence Dec 11, 2025 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory negative Insider Power Score of -86.15. Partially supported by a positive historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Apr 22, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Booth Bruce Director	Director	259 Value: $5K
Apr 22, 2026 Sell	Common Stock S-Sale	Booth Bruce Director	Director	12 Value: $1K
Apr 22, 2026 Sell	Common Stock S-Sale	Booth Bruce Director	Director	88 Value: $8K
Apr 22, 2026 Sell	Common Stock S-Sale	Booth Bruce Director	Director	5 900 Value: $530.8K
Apr 22, 2026 Buy	Common Stock M-Exempt	Booth Bruce Director	Director	5 641 Value: $80.0K
Apr 22, 2026 Buy	Common Stock M-Exempt	Booth Bruce Director	Director	259 Value: $5K
Apr 15, 2026 Sell	Common Stock S-Sale	Booth Bruce Director	Director	2 750 Value: $247.8K
Apr 15, 2026 Sell	Common Stock S-Sale	Booth Bruce Director	Director	385 Value: $34.7K
Apr 15, 2026 Sell	Common Stock S-Sale	Booth Bruce Director	Director	2 200 Value: $197.9K
Apr 15, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Chadwick Jeremy G Chief Operating Officer	C-Suite Officer	1 300 Value: $56.6K
Apr 15, 2026 Sell	Common Stock S-Sale	Chadwick Jeremy G Chief Operating Officer	C-Suite Officer	1 300 Value: $117.0K
Apr 15, 2026 Buy	Common Stock M-Exempt	Chadwick Jeremy G Chief Operating Officer	C-Suite Officer	1 300 Value: $56.6K
Apr 15, 2026 Buy	Common Stock M-Exempt	Booth Bruce Director	Director	2 200 Value: $31.2K
Apr 15, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Booth Bruce Director	Director	2 200 Value: $31.2K
Apr 14, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Booth Bruce Director	Director	4 159 Value: $59.0K
Apr 14, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Chadwick Jeremy G Chief Operating Officer	C-Suite Officer	4 466 Value: $134.7K
Apr 14, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Chadwick Jeremy G Chief Operating Officer	C-Suite Officer	785 Value: $34.1K
Apr 14, 2026 Buy	Common Stock M-Exempt	Chadwick Jeremy G Chief Operating Officer	C-Suite Officer	785 Value: $34.1K
Apr 14, 2026 Buy	Common Stock M-Exempt	Chadwick Jeremy G Chief Operating Officer	C-Suite Officer	4 466 Value: $134.7K
Apr 14, 2026 Sell	Common Stock S-Sale	Goodman Noah Chief Business Officer	Officer	1 347 Value: $121.2K
Apr 14, 2026 Sell	Common Stock S-Sale	Chadwick Jeremy G Chief Operating Officer	C-Suite Officer	5 251 Value: $472.6K
Apr 14, 2026 Buy	Common Stock M-Exempt	Booth Bruce Director	Director	4 159 Value: $59.0K
Apr 14, 2026 Sell	Common Stock S-Sale	Booth Bruce Director	Director	4 159 Value: $374.2K
Apr 10, 2026 Sell	Common Stock S-Sale	Goodman Noah Chief Business Officer	Officer	2 000 Value: $174.7K
Apr 09, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Goodman Noah Chief Business Officer	Officer	2 500 Value: $52.6K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT KYMERA THERAPEUTICS INC.

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation ...

Read Full Profile Here